A newly approved immunotherapy was effective for some forms of rectal cancer without the need for additional treatments.
The approval only covers a narrow group of rectal cancer patients, but for them it may rewrite what treatment looks like.
An individual participant data meta-analysis (IPDMA) found that patients who underwent laparoscopic liver resection (LLR) to ...
Some people with rectal cancer may now be able to skip chemotherapy, radiation and surgery. The U.S. Food and Drug ...
Patients assigned to receive high-dose eicosapentaenoic acid (EPA), an omega-3 fatty acid, before and after surgery for ...
In the previous article, I wrote about how I stopped chemotherapy for colorectal cancer after four sessions, and how my tumor ...
The FDA just approved Jemperli for some adults with locally advanced rectal cancer, offering an effective immunotherapy ...
Some people with rectal cancer may now be able to skip chemotherapy, radiation and surgery. The U.S. Food and Drug ...
A 5-year analysis supports watch-and-wait as an option for patients with locally advanced disease who have a complete response to neoadjuvant therapy.
A retrospective Chinese cohort study of 308 older colorectal cancer patients found that 55.52% carried preoperative frailty ...
The investigators concluded that AZUR-1 “demonstrates sustained clinical complete responses after dostarlimab monotherapy in ...
The cohort met its primary endpoint of major pathologic response, with 83% of patients having little or no cancer remaining ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results